



Docket No.: PF-0420-2 DIV

Response Under 37 C.F.R. 1.116 - Expedited Procedure
Examining Group 1644

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Mail Stop: Appeal Brief - Patents, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 26, 2003.

By: [Signature] Printed: Lisa McDill

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES**

RECEIVED
SEP 01 2003
TECH CENTER 1600/2800

In re Application of: Magna et al.

Title: HUMAN NUCLEOTIDE PYROPHOSPHOHYDROLASE-2
Serial No.: 09/757,716 Filing Date: January 9, 2001
Examiner: DeCloux, A.M. Group Art Unit: 1644

Mail Stop: Appeal Brief - Patents
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BRIEF ON APPEAL

Sir:

Further to the Notice of Appeal filed July 1, 2003, and received at the Patent Office on July 3, 2003, herewith are three copies of Appellants' Brief on Appeal. Authorized fees include the \$320 fee for the filing of this Brief.

This is an appeal from the decision of the Examiner finally rejecting claims 46, 48, 49, 51, 53-60, and 66-68 of the above-identified application.

(1) REAL PARTY IN INTEREST

The above-identified application is assigned of record to Incyte Pharmaceuticals, Inc. (now Incyte Corporation), (Reel 9851, Frames 0199 and 0206) who is the real party in interest herein.

08/29/2003 AMONDAF1 00000026 090100 09757716

01 FC:1402 320.00 DA
112988

(2) RELATED APPEALS AND INTERFERENCES

Appellants, their legal representative and the assignee are not aware of any related appeals or interferences which will directly affect or be directly affected by or have a bearing on the Board's decision in the instant appeal.

(3) STATUS OF THE CLAIMS

Claims rejected:	Claims 46, 48, 49, 51, 53-60, and 66-68
Claims allowed:	Claim 65
Claims canceled:	Claims 1-44, 50, 52, 63, and 64
Claims withdrawn:	Claims 45, 47, 61, and 62
Claims on Appeal:	Claims 46, 48, 49, 51, 53-60, and 66-68 (A copy of the claims on appeal, as amended, can be found in the attached Appendix.)

(4) STATUS OF AMENDMENTS AFTER FINAL

No amendments were submitted after Final Rejection.

(5) SUMMARY OF THE INVENTION

Appellants' invention is directed to antibodies which specifically bind to polypeptides, including nucleotide pyrophosphohydrolase NTPPH-2, comprising the amino acid sequence of SEQ ID NO:1 (Specification, e.g., at page 3, lines 17-19; page 4, lines 27-29; page 9, lines 15-17; page 30, lines 16-22; and page 31, lines 7-13). Appellants' invention also includes antibodies which specifically bind to polypeptides at least 90% identical to SEQ ID NO:1 (e.g., at page 17, lines 1-5), or to polypeptides which comprise fragments of SEQ ID NO:1 (e.g., at page 4, lines 27-29; page 9, lines 15-21; page 30, lines 23-25; and page 31, lines 7-13). The invention further includes compositions comprising the foregoing antibodies (e.g., at page 34, line 30 to page 35, line 4), and methods of making the foregoing antibodies (e.g., at page 30, line 15 to page 32, line 15; and page 55, line 28 to page 56, line 12).

NTPPH-2 has strong chemical and structural homology with a human nucleotide pyrophosphohydrolase, NTPPH-1 (Incyte ID 422069; SEQ ID NO:3) (Specification, e.g., at page 16, lines 15-16). In particular, NTPPH-2 and NTPPH-1 share 50% sequence identity (e.g., at page 16, lines 16-17; and Figures 2A, 2B, and 2C). In addition:

“NTPPH-2 is 1156 amino acids in length (Figures 1A-1K) and has three potential N-glycosylation sites at N₂₇₆, N₃₀₈, N₃₂₉, 25 potential phosphorylation sites at T₂₄, S₁₃₅, S₂₂₉, T₂₄₅, S₂₆₇, S₃₂₅, T₃₃₁, T₃₇₂, S₄₂₇, S₄₃₄, S₄₃₉, T₅₁₇, T₅₂₃, Y₅₉₉, T₆₀₈, S₆₃₀, T₇₅₀, T₈₄₇, S₈₈₃, Y₉₀₉, S₉₇₇, S₁₀₁₇, T₁₀₆₃, S₁₀₆₈, and T₁₁₄₉. . . As illustrated by Figures 3A and 3B, NTPPH-2 and NTPPH-1 have similar hydrophobicity plots and both show a hydrophobic signal sequence. The predicted isoelectric points for NTPPH-2 and NTPPH-1 are 8.07 and 8.21, respectively. Membrane-based northern analysis showed the highest level of NTPPH-2 mRNA expression in cartilage and lower, but significant, expression in testes, trachea, and bone marrow. Electronic northern analysis shows the expression of this sequence in various libraries, at least 57% of which involve immunological response and many of which are cartilage or joint related and at least 26% of which involve immortalized or cancerous cells and tissues. Of particular note is the expression of NTPPH-2 in rheumatoid and osteoarthritic synovial, chondrocyte, and tibial libraries.” (Specification at page 16, lines 12-30)

The antibodies of the present invention are useful, for example, for purifying and detecting polypeptides which have specific uses in toxicology testing, drug discovery, and disease diagnosis (Specification, e.g., at page 26, line 25 to page 27, line 3; page 38, line 14 to page 39, line 5; and page 46, lines 27-30).

(6) ISSUES

1. Whether claims 46, 48, 49, 51, 53-60, and 66-68 meet the written description requirement of 35 U.S.C. § 112, first paragraph.
2. Whether claims 46, 48, 49, 51, 53-60, and 66-68 meet the enablement requirement of 35 U.S.C. § 112, first paragraph.
3. Whether claims 46, 48, 49, 51, 53-60, and 66 meet the requirements of 35 U.S.C. § 112, second paragraph.

(7) GROUPING OF THE CLAIMS

As to Issue 1

Claims 46, 48, 49, 51, 53-60, and 66-68 are grouped together.

As to Issue 2

Claims 46, 48, 49, 51, 53-60, and 66-68 are grouped together.

As to Issue 3

Claims 46, 48, 49, 51, 53-60, and 66 are grouped together.

(8) APPELLANTS' ARGUMENTS

Issue 1 – Whether claims 46, 48, 49, 51, 53-60, and 66-68 meet the written description requirement of 35 U.S.C. § 112, first paragraph

Claims 46, 48, 49, 51, 53-60, and 66-68 stand rejected under 35 U.S.C. § 112, first paragraph, based on the allegation that the specification does not describe the subject matter in such a way as to reasonably convey to one of skill in the art that the inventors, at the time the application was filed, had possession of the claimed invention. The Examiner asserts that “the disclosure of SEQ ID NO:1 does not define the structural basis for the asserted and/or recited functional attributes of antibodies that bind the generically recited fragments and variants of SEQ ID NO:1” (Office Action, April 7, 2003; page 3). This rejection is traversed.

The requirements necessary to fulfill the written description requirement of 35 U.S.C. § 112, first paragraph, are well established by case law.

... the applicant must also convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the “written description” inquiry, *whatever is now claimed*. *Vas-Cath, Inc. v. Mahurkar*, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991)

Attention is also drawn to the Patent and Trademark Office's own "Guidelines for Examination of Patent Applications Under the 35 U.S.C. Sec. 112, para. 1", published January 5, 2001, which provide that:

An applicant may also show that an invention is complete by disclosure of sufficiently detailed, relevant identifying characteristics which provide evidence that applicant was in possession of the claimed invention, i.e., complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and structure, or some combination of such characteristics. What is conventional or well known to one of ordinary skill in the art need not be disclosed in detail. If a skilled artisan would have understood the inventor to be in possession of the claimed invention at the time of filing, even if every nuance of the claims is not explicitly described in the specification, then the adequate description requirement is met. [footnotes omitted]

Thus, the written description standard is fulfilled by both what is specifically disclosed and what is conventional or well known to one skilled in the art.

A. The specification provides an adequate written description of the claimed antibodies which specifically bind to the recited "variants" and "fragments" of SEQ ID NO:1.

The subject matter encompassed by claims 46, 48, 49, 51, 53-60, and 66-68 is either disclosed by the specification or is conventional or well known to one skilled in the art.

First note that the "variant" language of independent claim 46 recites polypeptides comprising "a polypeptide having a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1, wherein the polypeptide has nucleotide pyrophosphohydrolase activity." Furthermore, the "fragment" language of independent claim 46 recites polypeptides comprising "a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1, wherein the fragment has nucleotide pyrophosphohydrolase activity," and polypeptides comprising "an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1." The polypeptide sequence of SEQ ID NO:1 is explicitly disclosed in the specification. See, for example, the Sequence Listing and Figures 1A, 1B, 1C, 1D, 1E, 1F, 1G, 1H, 1I, 1J, 1K, 2A, 2B, and 2C. Variants of SEQ ID NO:1 are described in the specification at, for example, page 3, lines 20-22; page 8, lines 16-25;

page 8, line 30 to page 9, line 4; page 11, lines 13-15; page 13, lines 1-3; page 15, lines 4-5 and 16-24; page 17, lines 1-5; and page 21, lines 20-22; and fragments of SEQ ID NO:1 are described at, for example, page 3, lines 20-22 and 27-29; page 4, lines 24-29; page 8, lines 26-30; page 9, lines 15-28; page 10, lines 7-11; page 18, lines 6-11; page 21, lines 11-15; page 30, lines 23-25; page 31, lines 7-13; page 45, lines 28-30; page 55, lines 13-14; and page 55, line 28 to page 56, line 12. In addition, a specific assay to measure nucleotide pyrophosphohydrolase activity is disclosed in the specification at, for example, page 55, lines 22-26.

One of ordinary skill in the art would recognize polypeptide sequences which are variants that are at least 90% identical to SEQ ID NO:1. Given any naturally occurring polypeptide sequence, it would be routine for one of skill in the art to recognize whether it was a variant of SEQ ID NO:1. It would also be routine to determine whether such a variant had nucleotide pyrophosphohydrolase activity, using the disclosed nucleotide pyrophosphohydrolase assay. Accordingly, the specification provides an adequate written description of the claimed antibodies which specifically bind to the recited polypeptide variants of SEQ ID NO:1.

One of ordinary skill in the art would recognize polypeptide sequences which are fragments of SEQ ID NO:1. The amino acid sequence of SEQ ID NO:1 provides the necessary framework for the recited fragments - to recite every possible fragment would needlessly clutter the application. It would be routine for one of skill in the art to determine whether any particular fragment of SEQ ID NO:1 had nucleotide pyrophosphohydrolase activity, using the disclosed nucleotide pyrophosphohydrolase assay. Likewise, it would be routine for one of skill in the art to determine whether any particular fragment of SEQ ID NO:1 had immunogenic activity, based on the methods recited in the specification at, for example, page 9, lines 13-29; page 30, line 15 to page 32, line 15; and page 55, line 28 to page 56, line 12. Accordingly, the specification provides an adequate written description of the claimed antibodies which specifically bind to the recited polypeptide fragments of SEQ ID NO:1.

The Examiner asserts that "the structural basis of the recited functional limitations common to the claimed genus of fragments or variants is not disclosed, and thus one of skill could not readily distinguish between the genus of antibodies that specifically bind to fragments and variants of SEQ ID NO:1 that have nucleotide phosphorylase activity from the genus of antibodies that specifically bind to

fragments of SEQ ID NO:1 that do not have nucleotide phosphorylase activity” (Office Action, April 7, 2003; page 3). However, there is no requirement to provide a “structural basis” for the recited functional limitations in order for a skilled artisan to be able to distinguish antibodies that specifically bind to SEQ ID NO:1 variants and fragments having nucleotide pyrophosphohydrolase activity from antibodies that specifically bind to SEQ ID NO:1 variants and fragments lacking nucleotide pyrophosphohydrolase activity. A skilled artisan could distinguish one genus of antibodies from the other by determining whether any particular SEQ ID NO:1 variant or fragment, which is specifically bound by an antibody, has nucleotide pyrophosphohydrolase activity. For example, one of skill in the art could routinely make such a determination using the assay for nucleotide pyrophosphohydrolase activity disclosed in the specification at page 55, lines 22-26.

Furthermore, the Examiner asserts that one of skill in the art could not “readily distinguish between the genus of fragments of SEQ ID NO:1 that have biological activity from the genus of fragments of SEQ ID NO:1 that do not have biological activity” (Office Action, April 7, 2003; page 3; emphasis added). This assertion is irrelevant to the issue at hand because the claims recite fragments of SEQ ID NO:1 that have nucleotide pyrophosphohydrolase activity or immunogenic activity. As discussed above, one of skill in the art could routinely determine whether any particular fragment of SEQ ID NO:1 had nucleotide pyrophosphohydrolase activity by, for example, using the assay for nucleotide pyrophosphohydrolase activity disclosed in the specification at page 55, lines 22-26. Likewise, it would be routine for one of skill in the art to determine whether any particular fragment of SEQ ID NO:1 had immunogenic activity, based on the methods recited in the specification at, for example, page 9, lines 13-29; page 30, line 15 to page 32, line 15; and page 55, line 28 to page 56, line 12.

1. The present claims specifically define the claimed genus through the recitation of chemical structure

Court cases in which “DNA claims” have been at issue (which are hence relevant to claims to proteins encoded by the DNA) commonly emphasize that the recitation of structural features or chemical or physical properties are important factors to consider in a written description analysis of

such claims. For example, in *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993), the court stated that:

If a conception of a DNA requires a precise definition, such as by structure, formula, chemical name or physical properties, as we have held, then a description also requires that degree of specificity.

In a number of instances in which claims to DNA have been found invalid, the courts have noted that the claims attempted to define the claimed DNA in terms of functional characteristics without any reference to structural features. As set forth by the court in *University of California v. Eli Lilly and Co.*, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997):

In claims to genetic material, however, a generic statement such as “vertebrate insulin cDNA” or “mammalian insulin cDNA,” without more, is not an adequate written description of the genus because it does not distinguish the claimed genus from others, except by function.

Thus, the mere recitation of functional characteristics of a DNA, without the definition of structural features, has been a common basis by which courts have found invalid claims to DNA. For example, in *Lilly*, 43 USPQ2d at 1407, the court found invalid for violation of the written description requirement the following claim of U.S. Patent No. 4,652,525:

1. A recombinant plasmid replicable in procaryotic host containing within its nucleotide sequence a subsequence having the structure of the reverse transcript of an mRNA of a vertebrate, which mRNA encodes insulin.

In *Fiers*, 25 USPQ2d at 1603, the parties were in an interference involving the following count:

A DNA which consists essentially of a DNA which codes for a human fibroblast interferon-beta polypeptide.

Party Revel in the *Fiers* case argued that its foreign priority application contained an adequate written description of the DNA of the count because that application mentioned a potential method for isolating the DNA. The Revel priority application, however, did not have a description of any particular DNA structure corresponding to the DNA of the count. The court therefore found that the Revel priority application lacked an adequate written description of the subject matter of the count.

Thus, in *Lilly* and *Fiers*, nucleic acids were defined on the basis of functional characteristics and were found not to comply with the written description requirement of 35 U.S.C. § 112; *i.e.*, “an mRNA of a vertebrate, which mRNA encodes insulin” in *Lilly*, and “DNA which codes for a human fibroblast interferon-beta polypeptide” in *Fiers*. In contrast to the situation in *Lilly* and *Fiers*, the claims at issue in the present application define the polypeptides bound by the claimed antibodies in terms of chemical structure, rather than functional characteristics. For example, the language of independent claim 46 recites chemical structure to define the claimed genus:

46. An isolated antibody which specifically binds to a polypeptide comprising a polypeptide selected from the group consisting of:
- a) a polypeptide having the amino acid sequence of SEQ ID NO:1,
 - b) a polypeptide having a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1, wherein the polypeptide has nucleotide pyrophosphohydrolase activity,
 - c) a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1, wherein the fragment has pyrophosphohydrolase activity, and
 - d) an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1.

From the above it should be apparent that the claims of the subject application are fundamentally different from those found invalid in *Lilly* and *Fiers*. The subject matter of the present claims is defined in terms of the chemical structure of SEQ ID NO:1. In the present case, there is no reliance merely on a description of functional characteristics of the polypeptides specifically bound by the claimed antibodies. The polypeptides defined by the claims of the present application recite structural features, and cases such as *Lilly* and *Fiers* stress that the recitation of structure is an important factor to consider in a written description analysis of claims of this type. By failing to base the written description inquiry “on whatever is now claimed,” the Examiner failed to provide an appropriate analysis of the present claims and how they differ from those found not to satisfy the written description requirement in *Lilly* and *Fiers*.

The Patent Office Guidelines indicate that evidence that Appellants were in possession of the claimed invention can include “complete or partial structure, other physical and/or chemical properties, functional characteristics when coupled with a known or disclosed correlation between function and

structure, or some combination of such characteristics” (P.T.O. Guidelines, *supra*; emphasis added). The claimed antibodies which specifically bind the recited variants and fragments of the SEQ ID NO:1 polypeptide have been described by chemical structure (e.g., relation of the recited polypeptide variants and fragments to SEQ ID NO:1), physical properties (e.g., occurrence in nature of the recited polypeptide variants), and chemical properties (e.g., possession of nucleotide pyrophosphohydrolase activity by the recited polypeptide variants and fragments; specific binding of the claimed antibodies to the recited polypeptide variants and fragments). Therefore, the written description requirement has been met.

2. The present claims do not define a genus which is “highly variant”

Furthermore, the claims at issue do not describe a genus which could be characterized as “highly variant.” Available evidence illustrates that, rather than being a large variable genus, the claimed genus is of narrow scope.

In support of this assertion, the Examiner’s attention is directed to the enclosed reference by Brenner et al. (“Assessing sequence comparison methods with reliable structurally identified distant evolutionary relationships,” Proc. Natl. Acad. Sci. USA, 1998, 95:6073-6078). Through exhaustive analysis of a data set of proteins with known structural and functional relationships and with <90% overall sequence identity, Brenner et al. have determined that 30% identity is a reliable threshold for establishing evolutionary homology between two sequences aligned over at least 150 residues (Brenner et al., pages 6073 and 6076). Furthermore, local identity is particularly important in this case for assessing the significance of the alignments, as Brenner et al. further report that $\geq 40\%$ identity over at least 70 residues is reliable in signifying homology between proteins (Brenner et al., page 6076).

The present application is directed, *inter alia*, to antibodies which specifically bind to polypeptides which are nucleotide pyrophosphohydrolases, including polypeptides which are nucleotide pyrophosphohydrolases related to the amino acid sequence of SEQ ID NO:1. In accordance with Brenner et al., naturally occurring molecules may exist which could be characterized as nucleotide pyrophosphohydrolases and which have as little as 30% identity over at least 150 residues to SEQ ID NO:1. The “variant language” of the present claims recites a polypeptide comprising “a naturally

occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1” (note that SEQ ID NO:1 has 1156 amino acid residues). This variation is far less than that of all potential nucleotide pyrophosphohydrolases related to SEQ ID NO:1, i.e., those nucleotide pyrophosphohydrolases having as little as 30% identity over at least 150 residues to SEQ ID NO:1.

The Examiner asserts that “Applicant further contends that Brenner et al teach that 30% identity is a reliable threshold for establishing evolutionary homology between two sequences. However it is noted that the rejection is not based on the evolutionary homology between sequences but whether one of skill can envision the claimed genus of antibodies which bind polypeptides which have the disclosed asserted function of having nucleotide phosphorylase activity, from those that don’t” (Office Action, April 7, 2003; page 3). However, the Examiner’s arguments do not address the degree of variation within the recited genus of polypeptides which are specifically bound by the claimed antibodies. The Brenner et al. reference has been provided as evidence that the recited genus of polypeptides is not highly variant because the criteria used to define the structures of the members of the claimed genus (e.g., at least 90% identical to a reference sequence such as SEQ ID NO:1) are conservative relative to the broadest criteria which a skilled artisan would consider to be reasonable (e.g., the criteria of Brenner et al. that 30% identity over at least 150 residues, or 40% identity over at least 70 residues, reasonably denotes homology). Since the recited genus of polypeptides which are specifically bound by the claimed antibodies is not highly variant, one of skill in the art would reasonably understand that Appellants were in possession of the claimed invention at the time the application was filed.

3. The state of the art at the time of the present invention is further advanced than at the time of the *Lilly* and *Fiers* applications

In the *Lilly* case, claims of U.S. Patent No. 4,652,525 were found invalid for failing to comply with the written description requirement of 35 U.S.C. § 112. The ‘525 patent claimed the benefit of priority of two applications, Application Serial No. 801,343 filed May 27, 1977, and Application Serial No. 805,023 filed June 9, 1977. In the *Fiers* case, party Revel claimed the benefit of priority of an Israeli application filed on November 21, 1979. Thus, the written description inquiry in those cases was based on the state of the art at essentially the “dark ages” of recombinant DNA technology.

The present application has a priority date of December 22, 1997. Much has happened in the development of recombinant DNA technology in the 20 or so years from the time of filing of the applications involved in *Lilly* and *Fiers* and the present application. For example, the technique of polymerase chain reaction (PCR) was invented. Highly efficient cloning and DNA sequencing technology has been developed. Large databases of protein and nucleotide sequences have been compiled. Much of the raw material of the human and other genomes has been sequenced. With these remarkable advances, one of skill in the art would recognize that, given the sequence information of SEQ ID NO:1, and the additional extensive detail provided by the subject application, the present inventors were in possession of the claimed antibodies which specifically bind the recited polypeptide variants and fragments at the time of filing of this application.

4. Summary

The Examiner failed to base the written description inquiry “on whatever is now claimed.” Consequently, the Examiner did not provide an appropriate analysis of the present claims and how they differ from those found not to satisfy the written description requirement in cases such as *Lilly* and *Fiers*. In particular, the claims of the subject application are fundamentally different from those found invalid in *Lilly* and *Fiers*. The subject matter of the present claims is defined in terms of the chemical structure of SEQ ID NO:1. The courts have stressed that structural features are important factors to consider in a written description analysis of claims to nucleic acids and proteins. In addition, the genus of polypeptides recited by the present claims is adequately described, as evidenced by Brenner et al. Furthermore, there have been remarkable advances in the state of the art since the *Lilly* and *Fiers* cases, and these advances were given no consideration whatsoever in the position set forth by the Examiner.

For at least the reasons set forth above, the specification provides an adequate written description of the claimed antibodies which specifically bind to the recited polypeptide “variants” and “fragments,” and this rejection should be overturned.

Issue 2 – Whether claims 46, 48, 49, 51, 53-60, and 66-68 meet the enablement requirement of 35 U.S.C. § 112, first paragraph

Claims 46, 48, 49, 51, 53-60, and 66-68 stand rejected under 35 U.S.C. § 112, first paragraph, based on the allegation that the specification does not describe the subject matter of the invention in such a way as to enable one of skill in the art to make and/or use antibodies which specifically bind to the recited “variants” and “fragments” of SEQ ID NO:1. In particular, the Examiner asserts that “there is insufficient direction regarding how to make and use an antibody that specifically binds to any fragment or variant of SEQ ID NO:1, said variants and fragments encompassing a wide range of polypeptides” (Office Action, April 7, 2003; page 4). Such, however, is not the case.

The specification discloses methods to make antibodies which specifically bind to a polypeptide having any particular amino acid sequence (e.g., at page 30, line 15 to page 32, line 15; and page 55, line 28 to page 56, line 12). Given the information provided by SEQ ID NO:1 (the amino acid sequence of NTPPH-2), one of skill in the art would be able to routinely obtain antibodies which specifically bind to any of the recited variants and fragments of SEQ ID NO:1, including a polypeptide comprising “a polypeptide having a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1, wherein the polypeptide has nucleotide pyrophosphohydrolase activity,” a polypeptide comprising “a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1, wherein the fragment has pyrophosphohydrolase activity,” and a polypeptide comprising “an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1.” For example, an animal could be immunized with any of the recited variants and fragments of SEQ ID NO:1, antibodies could be isolated from the animal, and the antibodies could be screened to identify antibodies which specifically bind to the polypeptide.

Likewise, the specification discloses methods to use antibodies which specifically bind to a polypeptide having any particular amino acid sequence in, for example, the purification of such polypeptides (e.g., at page 56, lines 14-24), the detection and/or measurement of such polypeptides (e.g., at page 26, line 25 to page 27, line 3; and page 38, line 14 to page 39, line 5), and the competitive screening of drug candidates (e.g., at page 46, lines 27-30). Given the information provided by SEQ ID NO:1 (the amino acid sequence of NTPPH-2), one of skill in the art would be

able to routinely use antibodies which specifically bind to any of the recited variants and fragments of SEQ ID NO:1, including a polypeptide comprising “a polypeptide having a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1, wherein the polypeptide has nucleotide pyrophosphohydrolase activity,” a polypeptide comprising “a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1, wherein the fragment has nucleotide pyrophosphohydrolase activity,” and a polypeptide comprising “an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1.” For example, an antibody which specifically binds to any of the recited variants and fragments of SEQ ID NO:1 could be coupled to an activated chromatographic resin, and this resin could then be used in an immunoaffinity column to purify the polypeptide.

In support of this rejection, the Examiner has stated that “the specification does not appear to disclose the sequence of any said polypeptides comprising an amino acid sequence at least 90% identical to an amino acid sequence of SEQ ID NO:1” (Office Action, October 21, 2002; page 6). Furthermore, the Examiner has asserted that “[t]he specification does not appear to disclose or exemplify any said biologically active or immunogenic fragments of a polypeptide having an amino acid sequence of SEQ ID NO:1” (*Id.*). The Examiner is incorrect in asserting that the recited polypeptide variants and fragments which are specifically bound by the claimed antibodies are not disclosed by the specification. Variants of SEQ ID NO:1 are disclosed in the specification at, for example, page 3, lines 20-22; page 8, lines 16-25; page 8, line 30 to page 9, line 4; page 15, lines 16-24; page 17, lines 1-5; and page 21, lines 20-22. Fragments of SEQ ID NO:1 are disclosed in the specification at, for example, page 3, lines 20-22 and 27-29; page 8, lines 26-30; page 9, lines 15-28; page 10, lines 7-11; page 30, lines 23-25; page 31, lines 7-13; and page 55, line 28 to page 56, line 12. In addition, an assay to measure nucleotide pyrophosphohydrolase activity is disclosed in the specification at, for example, page 55, lines 22-26. Therefore, the recited polypeptide variants and fragments are fully disclosed in the specification. Furthermore, antibodies which specifically bind to NTPPH-2, and variants and fragments thereof, are disclosed in the specification at, for example, page 4, lines 27-29; page 9, lines 13-21; and page 31, lines 7-13.

Furthermore, the Examiner has argued that “[w]ithout knowing the function of the polypeptides related to a polypeptide comprising an amino acid sequence comprising SEQ ID NO:1, it would require undue experimentation for one of skill to predict the function of antibodies which specifically binds to said polypeptides” (Office Action, October 21, 2002; pages 6-7). This is incorrect. No undue experimentation would be required because it is a trivial matter to “predict the function of antibodies” which specifically bind to the recited polypeptides. The “function” of such antibodies is to specifically bind to the recited polypeptides, and a skilled artisan would recognize this immediately.

Moreover, it would not require undue experimentation to make and use the claimed antibodies. Antibodies which specifically bind to a polypeptide can be made as long as that polypeptide, or fragments thereof, are available; there is no restriction on the amino acid sequence of polypeptides that can be used to make antibodies. Since a polypeptide having any amino acid sequence (including any amino acid sequence that is 90% identical to SEQ ID NO:1, any naturally occurring amino acid sequence that is 90% identical to SEQ ID NO:1, and any fragment of SEQ ID NO:1) can be used to make antibodies using the methods disclosed in the specification, it is not necessary to identify particular naturally occurring amino acid sequences that are 90% identical to SEQ ID NO:1, or particular fragments of SEQ ID NO:1, that could be used in this manner.

The Examiner states that “the rejection is based on the scope of the claimed variants and fragments of the polypeptides to which said antibodies specifically bind” (Office Action, April 7, 2003; page 4). In particular, the Examiner asserts that “the problem of predicting what changes can be tolerated while still maintaining the functional nucleotide phosphorylase activity of the recited variants and fragments of SEQ ID NO:1, based on the sequence data of a single amino acid sequence (SEQ ID NO:1), is complex and well outside the realm of routine experimentation” and that “even a single amino acid change in a polypeptide’s amino acid sequence can have dramatic effects on its function” (*Id.*). In support of these assertions, the Examiner has cited Sugie et al. (Proc. Natl. Acad. Sci. USA, 1997, 94:5278-5283). This reference teaches that human glycosylation-inhibiting factor differs from human macrophage migration inhibitory factor by one amino acid residue, and yet these proteins do not share all of their biological functions (Office Action, October 21, 2002; page 6).

However, the Examiner's assertions are irrelevant because it is not necessary to predict what changes in SEQ ID NO:1 "can be tolerated while still maintaining the functional nucleotide phosphorylase activity" in order to make and/or use the claimed antibodies. For example, the claimed antibodies include antibodies which specifically bind to a polypeptide comprising "a polypeptide having a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1, wherein the polypeptide has nucleotide pyrophosphohydrolase activity," and to a polypeptide comprising "a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1, wherein the fragment has nucleotide pyrophosphohydrolase activity." An assay to measure nucleotide pyrophosphohydrolase activity is disclosed in the specification at, for example, page 55, lines 22-26. One of ordinary skill in the art could routinely use the disclosed assay to identify polypeptide variants and fragments recited by the claims. One could then routinely make and/or use antibodies which specifically bind to these polypeptide variants and fragments. Contrary to the Examiner's assertions, no undue experimentation would be required.

As set forth in *In re Marzocchi*, 169 USPQ 367, 369 (CCPA 1971):

The first paragraph of § 112 requires nothing more than objective enablement. How such a teaching is set forth, either by the use of illustrative examples or by broad terminology, is of no importance.

As a matter of Patent Office practice, then, a specification disclosure which contains a teaching of the manner and process of making and using the invention in terms which correspond in scope to those used in describing and defining the subject matter sought to be patented *must* be taken as in compliance with the enabling requirement of the first paragraph of § 112 *unless* there is reason to doubt the objective truth of the statements contained therein which must be relied on for enabling support.

Contrary to the standard set forth in *Marzocchi*, the Examiner has failed to provide any reasons why one would doubt that the guidance provided by the present specification would enable one to make and use the claimed antibodies which specifically bind to the recited variants and fragments of SEQ ID NO:1. Hence, a *prima facie* case for non-enablement has not been established with respect to the claimed antibodies which specifically bind to the recited variants and fragments of SEQ ID NO:1.

For at least the above reasons, reversal of this rejection is requested.

Issue 3 – Whether claims 46, 48, 49, 51, 53-60, and 66 meet the requirements of 35 U.S.C. § 112, second paragraph

Claims 46, 48-49, 51, 53-60, and 66 were rejected under 35 U.S.C. § 112, second paragraph, based on the allegation that the recitation of “at least 90% identical” is indefinite. The Examiner asserts that “the algorithm used to define identity is not disclosed in the specification,” and that “[i]t is not clear how an amino acid sequence can have homology to another amino acid sequence” (Office Action, April 7, 2003; page 4). This rejection is traversed.

Under the second paragraph of 35 U.S.C. § 112, the standard for “definiteness” is that the claims define patentable subject matter with a **reasonable** degree of precision and particularity. See *In re Miller*, 169 USPQ 597, 599 (CCPA 1971); *In re Moore*, 169 USPQ 236, 238 (CCPA 1971). See also M.P.E.P. § 706.03(d). In this regard, the Supreme Court has indicated that the primary purpose of claim language is to give “fair” notice of what would constitute the infringement of a claim. See *United Carbon Co. v. Binny & Smith Co.*, 317 U.S. 228, 55 USPQ 381 (1942). In other words, the basic purpose of 35 U.S.C. § 112, second paragraph is to require a claim to reasonably apprise those skilled in the art of the scope of the invention defined by that claim and give fair notice of what constitutes infringement of the claim. See *Antonius v. Pro Group Inc.*, 217 USPQ 875, 877 (6th Cir.1983). The present claims meet the legal standards required by 35 U.S.C. § 112, second paragraph.

One of ordinary skill in the art would understand the meaning of the term “at least 90% identical” when this term is used for defining the structure of an amino acid sequence in relation to a reference amino acid sequence, as in the claims at issue. The Examiner recognizes this in stating that the term “identity” is “defined in the specification on page 11, by stating that the term identity may substituted for the term homology and **refers to a degree of complementarity**” (Office Action, April 7, 2003; page 4; emphasis added). However, the Examiner errs in requiring an explicit disclosure of the algorithm used to calculate percent identity. A skilled artisan would reasonably understand that percent identity is simply the percentage of amino acid residues in a polypeptide sequence which are

identical to those in a reference sequence. Moreover, a skilled artisan would know that the percent identity between two amino acid sequences can be calculated using basic mathematics. For example, to arrive at the percent identity, a subject sequence and a reference sequence are compared, the number of amino acids which are identical in these sequences is summed up, and the result is divided by the total number of amino acids in the reference sequence. Therefore, the claims are definite in their recitation of amino acid sequences which are "at least 90% identical" to the amino acid sequence of SEQ ID NO:1.

The Examiner insists that grounds for indefiniteness include "that there are several programs that use different algorithms to determine homology, and that the specification discloses no specific single algorithm" (Office Action, April 7, 2003; page 5). However, the Examiner provides no evidence to support these assertions. Calculations of percent identity between sequences, regardless of the algorithm used, are essentially the division of the number of identical amino acid residues by the total number of amino acid residues. Even if it were true that there are several programs using different algorithms to carry out such calculations, one of skill in the art would nevertheless understand the basic calculation underlying all such algorithms. Thus, there is no need for a disclosure of only a single algorithm to determine percent identity in order to satisfy the requirements of the second paragraph of 35 U.S.C. § 112. All that is necessary to satisfy the second paragraph of 35 U.S.C. § 112 is that one of skill in the art be able to reasonably determine what is within the scope of the claim. In the present case, one of skill in the art would reasonably understand whether any particular polypeptide sequence was at least 90% identical to SEQ ID NO:1, without needing a disclosure of only a single program or algorithm.

For at least the above reasons, reversal of this rejection under 35 U.S.C. § 112, second paragraph, is requested.

(9) CONCLUSION

The written description rejections, enablement rejections, and indefiniteness rejections should be reversed, based on at least the arguments presented above.

Due to the urgency of this matter, and its economic and public health implications, an expedited review of this appeal is earnestly solicited.


If the USPTO determines that any additional fees are due, the Commissioner is hereby authorized to charge Deposit Account No. **09-0108**.

This brief is enclosed in triplicate.

Respectfully submitted,

INCYTE CORPORATION

Date: August 26, 2003.



Terence P. Lo, Ph.D.

Limited Recognition (37 C.F.R. § 10.9(b)) attached

Direct Dial Telephone: (650) 621-8581

Customer No.: 27904
3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

APPENDIX

Claims on appeal:

46. An isolated antibody which specifically binds to a polypeptide comprising a polypeptide selected from the group consisting of:

- a) a polypeptide having the amino acid sequence of SEQ ID NO:1,
- b) a polypeptide having a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1, wherein the polypeptide has nucleotide pyrophosphohydrolase activity,
- c) a fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1, wherein the fragment has nucleotide pyrophosphohydrolase activity, and
- d) an immunogenic fragment of a polypeptide having the amino acid sequence of SEQ ID NO:1.

48. The antibody of claim 46, wherein the antibody is:

- a) a chimeric antibody,
- b) a single chain antibody,
- c) a Fab fragment,
- d) a F(ab')₂ fragment, or
- e) a humanized antibody.

49. A composition comprising an antibody of claim 46 and an acceptable excipient.

51. A composition of claim 49, further comprising a label.

53. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 46, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence of SEQ ID NO:1, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibodies from said animal, and
- c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.

54. A polyclonal antibody produced by a method of claim 53.

55. A composition comprising the antibody of claim 54 and a suitable carrier.

56. A method of making a monoclonal antibody with the specificity of the antibody of claim 46, the method comprising:

- a) immunizing an animal with a polypeptide having an amino acid sequence of SEQ ID NO:1, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
- b) isolating antibody producing cells from the animal,
- c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
- d) culturing the hybridoma cells, and
- e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence of SEQ ID NO:1.

57. A monoclonal antibody produced by a method of claim 56.

58. A composition comprising the antibody of claim 57 and a suitable carrier.

59. The antibody of claim 46, wherein the antibody is produced by screening a Fab expression library.

60. The antibody of claim 46, wherein the antibody is produced by screening a recombinant immunoglobulin library.

66. An isolated antibody of claim 46, which specifically binds to a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:1, wherein the polypeptide has nucleotide pyrophosphohydrolase activity.

67. An isolated antibody of claim 46, which specifically binds to a fragment of a polypeptide, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:1, and wherein the fragment has nucleotide pyrophosphohydrolase activity.

68. An isolated antibody of claim 46, which specifically binds to an immunogenic fragment of a polypeptide, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:1.

Proc. Natl. Acad. Sci. USA
Vol. 95, pp. 6073–6078, May 1998
Biochemistry

Assessing sequence comparison methods with reliable structurally identified distant evolutionary relationships

STEVEN E. BRENNER^{*†‡}, CYRUS CHOTHIA^{*}, AND TIM J. P. HUBBARD[§]

^{*}MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, United Kingdom; and [†]Sanger Centre, Wellcome Trust Genome Campus, Hinxton, Cambs CB10 1SA, United Kingdom

Communicated by David R. Davies, National Institute of Diabetes, Bethesda, MD, March 16, 1998 (received for review November 12, 1997)

ABSTRACT Pairwise sequence comparison methods have been assessed using proteins whose relationships are known reliably from their structures and functions, as described in the SCOP database [Murzin, A. G., Brenner, S. E., Hubbard, T. & Chothia C. (1995) *J. Mol. Biol.* 247, 536–540]. The evaluation tested the programs BLAST [Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) *J. Mol. Biol.* 215, 403–410], WU-BLAST2 [Altschul, S. F. & Gish, W. (1996) *Methods Enzymol.* 266, 460–480], FASTA [Pearson, W. R. & Lipman, D. J. (1988) *Proc. Natl. Acad. Sci. USA* 85, 2444–2448], and SSEARCH [Smith, T. F. & Waterman, M. S. (1981) *J. Mol. Biol.* 147, 195–197] and their scoring schemes. The error rate of all algorithms is greatly reduced by using statistical scores to evaluate matches rather than percentage identity or raw scores. The E-value statistical scores of SSEARCH and FASTA are reliable: the number of false positives found in our tests agrees well with the scores reported. However, the P-values reported by BLAST and WU-BLAST2 exaggerate significance by orders of magnitude. SSEARCH, FASTA $ktup = 1$, and WU-BLAST2 perform best, and they are capable of detecting almost all relationships between proteins whose sequence identities are >30%. For more distantly related proteins, they do much less well; only one-half of the relationships between proteins with 20–30% identity are found. Because many homologs have low sequence similarity, most distant relationships cannot be detected by any pairwise comparison method; however, those which are identified may be used with confidence.

Sequence database searching plays a role in virtually every branch of molecular biology and is crucial for interpreting the sequences issuing forth from genome projects. Given the method's central role, it is surprising that overall and relative capabilities of different procedures are largely unknown. It is difficult to verify algorithms on sample data because this requires large data sets of proteins whose evolutionary relationships are known unambiguously and independently of the methods being evaluated. However, nearly all known homologs have been identified by sequence analysis (the method to be tested). Also, it is generally very difficult to know, in the absence of structural data, whether two proteins that lack clear sequence similarity are unrelated. This has meant that although previous evaluations have helped improve sequence comparison, they have suffered from insufficient, imperfectly characterized, or artificial test data. Assessment also has been problematic because high quality database sequence searching attempts to have both sensitivity (detection of homologs) and specificity (rejection of unrelated proteins); however, these complementary goals are linked such that increasing one causes the other to be reduced.

Sequence comparison methodologies have evolved rapidly, so no previously published tests have evaluated modern versions of programs commonly used. For example, parameters in BLAST (1) have changed, and WU-BLAST2 (2)—which produces gapped alignments—has become available. The latest version of FASTA (3) previously tested was 1.6, but the current release (version 3.0) provides fundamentally different results in the form of statistical scoring.

The previous reports also have left gaps in our knowledge. For example, there has been no published assessment of thresholds for scoring schemes more sophisticated than percentage identity. Thus, the widely discussed statistical scoring measures have never actually been evaluated on large databases of real proteins. Moreover, the different scoring schemes commonly in use have not been compared.

Beyond these issues, there is a more fundamental question: in an absolute sense, how well does pairwise sequence comparison work? That is, what fraction of homologous proteins can be detected using modern database searching methods?

In this work, we attempt to answer these questions and to overcome both of the fundamental difficulties that have hindered assessment of sequence comparison methodologies. First, we use the set of distant evolutionary relationships in the SCOP: Structural Classification of Proteins database (4), which is derived from structural and functional characteristics (5). The SCOP database provides a uniquely reliable set of homologs, which are known independently of sequence comparison. Second, we use an assessment method that jointly measures both sensitivity and specificity. This method allows straightforward comparison of different sequence searching procedures. Further, it can be used to aid interpretation of real database searches and thus provide optimal and reliable results.

Previous Assessments of Sequence Comparison. Several previous studies have examined the relative performance of different sequence comparison methods. The most encompassing analyses have been by Pearson (6, 7), who compared the three most commonly used programs. Of these, the Smith-Waterman algorithm (8) implemented in SSEARCH (3) is the oldest and slowest but the most rigorous. Modern heuristics have provided BLAST (1) the speed and convenience to make it the most popular program. Intermediate between these two is FASTA (3), which may be run in two modes offering either greater speed ($ktup = 2$) or greater effectiveness ($ktup = 1$). Pearson also considered different parameters for each of these programs.

To test the methods, Pearson selected two representative proteins from each of 67 protein superfamilies defined by the PIR database (9). Each was used as a query to search the database, and the matched proteins were marked as being homologous or unrelated according to their membership of PIR

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

© 1998 by The National Academy of Sciences 0027-8424/98/956073-6\$2.00/0
PNAS is available online at <http://www.pnas.org>.

Abbreviation: EPO, errors per query.

[†]Present address: Department of Structural Biology, Stanford University, Fairchild Building D-109, Stanford, CA 94305-5126

[‡]To whom reprints requests should be addressed. e-mail: brenner@hyper.stanford.edu.

superfamilies. Pearson found that modern matrices and "ln-scaling" of raw scores improve results considerably. He also reported that the rigorous Smith-Waterman algorithm worked slightly better than FASTA, which was in turn more effective than BLAST.

Very large scale analyses of matrices have been performed (10), and Henikoff and Henikoff (11) also evaluated the effectiveness of BLAST and FASTA. Their test with BLAST considered the ability to detect homologs above a predetermined score but had no penalty for methods which also reported large numbers of spurious matches. The Henikoffs searched the SWISS-PROT database (12) and used PROSITE (13) to define homologous families. Their results showed that the BLOSUM62 matrix (14) performed markedly better than the extrapolated PAM-series matrices (15), which previously had been popular.

A crucial aspect of any assessment is the data that are used to test the ability of the program to find homologs. But in Pearson's and the Henikoffs' evaluations of sequence comparison, the correct results were effectively unknown. This is because the superfamilies in PIR and PROSITE are principally created by using the same sequence comparison methods which are being evaluated. Interdependency of data and methods creates a "chicken and egg" problem, and means for example, that new methods would be penalized for correctly identifying homologs missed by older programs. For instance, immunoglobulin variable and constant domains are clearly homologous, but PIR places them in different superfamilies. The problem is widespread: each superfamily in PIR 48.00 with a structural homolog is itself homologous to an average of 1.6 other PIR superfamilies (16).

To surmount these sorts of difficulties, Sander and Schneider (17) used protein structures to evaluate sequence comparison. Rather than comparing different sequence comparison algorithms, their work focused on determining a length-dependent threshold of percentage identity, above which all proteins would be of similar structure. A result of this analysis was the HSSP equation; it states that proteins with 25% identity over 80 residues will have similar structures, whereas shorter alignments require higher identity. (Other studies also have used structures (18–20), but these focused on a small number of model proteins and were principally oriented toward evaluating alignment accuracy rather than homology detection.)

A general solution to the problem of scoring comes from statistical measures (i.e., E-values and P-values) based on the extreme value distribution (21). Extreme value scoring was implemented analytically in the BLAST program using the Karlin and Altschul statistics (22, 23) and empirical approaches have been recently added to FASTA and SSEARCH. In addition to being heralded as a reliable means of recognizing significantly similar proteins (24, 25), the mathematical tractability of statistical scores "is a crucial feature of the BLAST algorithm" (1). The validity of this scoring procedure has been tested analytically and empirically (see ref. 2 and references in ref. 24). However, all large empirical tests used random sequences that may lack the subtle structure found within biological sequences (26, 27) and obviously do not contain any real homologs. Thus, although many researchers have suggested that statistical scores be used to rank matches (24, 25, 28), there have been no large rigorous experiments on biological data to determine the degree to which such rankings are superior.

A Database for Testing Homology Detection. Since the discovery that the structures of hemoglobin and myoglobin are very similar though their sequences are not (29), it has been apparent that comparing structures is a more powerful (if less convenient) way to recognize distant evolutionary relationships than comparing sequences. If two proteins show a high degree of similarity in their structural details and function, it

is very probable that they have an evolutionary relationship though their sequence similarity may be low.

The recent growth of protein structure information combined with the comprehensive evolutionary classification in the SCOP database (4, 5) have allowed us to overcome previous limitations. With these data, we can evaluate the performance of sequence comparison methods on real protein sequences whose relationships are known confidently. The SCOP database uses structural information to recognize distant homologs, the large majority of which can be determined unambiguously. These superfamilies, such as the globins or the immunoglobulins, would be recognized as related by the vast majority of the biological community despite the lack of high sequence similarity.


From SCOP, we extracted the sequences of domains of proteins in the Protein Data Bank (PDB) (30) and created two databases. One (PDB90D-B) has domains, which were all <90% identical to any other, whereas (PDB40D-B) had those <40% identical. The databases were created by first sorting all protein domains in SCOP by their quality and making a list. The highest quality domain was selected for inclusion in the database and removed from the list. Also removed from the list (and discarded) were all other domains above the threshold level of identity to the selected domain. This process was repeated until the list was empty. The PDB40D-B database contains 1,323 domains, which have 9,044 ordered pairs of distant relationships, or ~0.5% of the total 1,749,006 ordered pairs. In PDB90D-B, the 2,079 domains have 53,988 relationships, representing 1.2% of all pairs. Low complexity regions of sequence can achieve spurious high scores, so these were masked in both databases by processing with the SEG program (27) using recommended parameters: 12 1.8 2.0. The databases used in this paper are available from <http://sss.stanford.edu/sss/>, and databases derived from the current version of SCOP may be found at <http://scop.mrc-lmb.cam.ac.uk/scop/>.

Analyses from both databases were generally consistent, but PDB40D-B focuses on distantly related proteins and reduces the heavy overrepresentation in the PDB of a small number of families (31, 32), whereas PDB90D-B (with more sequences) improves evaluations of statistics. Except where noted otherwise, the distant homolog results here are from PDB40D-B. Although the precise numbers reported here are specific to the structural domain databases used, we expect the trends to be general.

Assessment Data and Procedure. Our assessment of sequence comparison may be divided into four different major categories of tests. First, using just a single sequence comparison algorithm at a time, we evaluated the effectiveness of different scoring schemes. Second, we assessed the reliability of scoring procedures, including an evaluation of the validity of statistical scoring. Third, we compared sequence comparison algorithms (using the optimal scoring scheme) to determine their relative performance. Fourth, we examined the distribution of homologs and considered the power of pairwise sequence comparison to recognize them. All of the analyses used the databases of structurally identified homologs and a new assessment criterion.

The analyses tested BLAST (1), version 1.4.9MP, and WU-BLAST2 (2), version 2.0a13MP. Also assessed was the FASTA package, version 3.0i76 (3), which provided FASTA and the SSEARCH implementation of Smith-Waterman (8). For SSEARCH and FASTA, we used BLOSUM45 with gap penalties -12/-1 (7, 16). The default parameters and matrix (BLOSUM62) were used for BLAST and WU-BLAST2.

The "Coverage Vs. Error" Plot. To test a particular protocol (comprising a program and scoring scheme), each sequence from the database was used as a query to search the database. This yielded ordered pairs of query and target sequences with associated scores, which were sorted, on the basis of their scores, from best to worst. The ideal method would have



perfect separation, with all of the homologs at the top of the list and unrelated proteins below. In practice, perfect separation is impossible to achieve so instead one is interested in drawing a threshold above which there are the largest number of related pairs of sequences consistent with an acceptable error rate.

Our procedure involved measuring the coverage and error for every threshold. Coverage was defined as the fraction of structurally determined homologs that have scores above the selected threshold; this reflects the sensitivity of a method. Errors per query (EPQ), an indicator of selectivity, is the number of nonhomologous pairs above the threshold divided by the number of queries. Graphs of these data, called coverage vs. error plots, were devised to understand how

protocols compare at different levels of accuracy. These graphs share effectively all of the beneficial features of Receiver Operating Characteristic (ROC) plots (33, 34) but better represent the high degrees of accuracy required in sequence comparison and the huge background of nonhomologs.

This assessment procedure is directly relevant to practical sequence database searching, for it provides precisely the information necessary to perform a reliable sequence database search. The EPQ measure places a premium on score consistency; that is, it requires scores to be comparable for different queries. Consistency is an aspect which has been largely





FIG. 3. Length and percentage identity of alignments of unrelated proteins in PDB900-B: Each pair of nonhomologous proteins found with SSEARCH is plotted as a point whose position indicates the length and the percentage identity within the alignment. Because alignment length and percentage identity are quantized, many pairs of proteins may have exactly the same alignment length and percentage identity. The line shows the HSSP threshold (though it is intended to be applied with a different matrix and parameters).




FIG. 4. Reliability of statistical scores in PDB90D-B: Each line shows the relationship between reported statistical score and actual error rate for a different program. E-values are reported for SSEARCH and FASTA, whereas P-values are shown for BLAST and WU-BLAST2. If the scoring were perfect, then the number of errors per query and the E-values would be the same, as indicated by the upper bold line. (P-values should be the same as EPO for small numbers, and diverges at higher values, as indicated by the lower bold line.) E-values from SSEARCH and FASTA are shown to have good agreement with EPO but underestimate the significance slightly. BLAST and WU-BLAST2 are overconfident, with the degree of exaggeration dependent upon the score. The results for PDB40D-B were similar to those for PDB90D-B despite the difference in number of homologs detected. This graph could be used to roughly calibrate the reliability of a given statistical score.

ignored in previous tests but is essential for the straightforward or automatic interpretation of sequence comparison results. Further, it provides a clear indication of the confidence that should be ascribed to each match. Indeed, the EPO measure should approximate the expectation value reported by database searching programs, if the programs' estimates are accurate.

The Performance of Scoring Schemes. All of the programs tested could provide three fundamental types of scores. The first score is the percentage identity, which may be computed in several ways based on either the length of the alignment or the lengths of the sequences. The second is a "raw" or "Smith-Waterman" score, which is the measure optimized by the Smith-Waterman algorithm and is computed by summing the substitution matrix scores for each position in the alignment and subtracting gap penalties. In BLAST, a measure

related to this score is scaled into bits. Third is a statistical score based on the extreme value distribution. These results are summarized in Fig. 1.

Sequence Identity. Though it has been long established that percentage identity is a poor measure (35), there is a common rule-of-thumb stating that 30% identity signifies homology. Moreover, publications have indicated that 25% identity can be used as a threshold (17, 36). We find that these thresholds, originally derived years ago, are not supported by present results. As databases have grown, so have the possibilities for chance alignments with high identity; thus, the reported cutoffs lead to frequent errors. Fig. 2 shows one of the many pairs of proteins with very different structures that nonetheless have high levels of identity over considerable aligned regions. Despite the high identity, the raw and the statistical scores for such incorrect matches are typically not significant. The principal reasons percentage identity does so poorly seem to be that it ignores information about gaps and about the conservative or radical nature of residue substitutions.

From the PDB90D-B analysis in Fig. 3, we learn that 30% identity is a reliable threshold for this database only for sequence alignments of at least 150 residues. Because one unrelated pair of proteins has 43.5% identity over 62 residues, it is probably necessary for alignments to be at least 70 residues in length before 40% is a reasonable threshold, for a database of this particular size and composition.

At a given reliability, scores based on percentage identity detect just a fraction of the distant homologs found by statistical scoring. If one measures the percentage identity in the aligned regions without consideration of alignment length, then a negligible number of distant homologs are detected. Use of the HSP equation improves the value of percentage identity, but even this measure can find only 4% of all known homologs at 1% EPQ. In short, percentage identity discards most of the information measured in a sequence comparison.

Raw Scores. Smith-Waterman raw scores perform better than percentage identity (Fig. 1), but ln-scaling (7) provided no notable benefit in our analysis. It is necessary to be very precise when using either raw or bit scores because a 20% change in cutoff score could yield a tenfold difference in EPQ. However, it is difficult to choose appropriate thresholds because the reliability of a bit score depends on the lengths of the proteins matched and the size of the database. Raw score thresholds also are affected by matrix and gap parameters.

Statistical Scores. Statistical scores were introduced partly to overcome the problems that arise from raw scores. This scoring scheme provides the best discrimination between homologous proteins and those which are unrelated. Most





FIG. 5. Coverage vs. error plots of different sequence comparison methods: Five different sequence comparison methods are evaluated, each using statistical scores (E- or P-values). (A) PDB40D-B database. In this analysis, the best method is the slow SSEARCH, which finds 18% of relationships at 1% EPQ. FASTA ktup = 1 and WU-BLAST2 are almost as good. (B) PDB90D-B database. The quick WU-BLAST2 program provides the best coverage at 1% EPQ on this database, although at higher levels of error it becomes slightly worse than FASTA ktup = 1 and SSEARCH.

likely, its power can be attributed to its incorporation of more information than any other measure; it takes account of the full substitution and gap data (like raw scores) but also has details about the sequence lengths and composition and is scaled appropriately.

We find that statistical scores are not only powerful, but also easy to interpret. SSEARCH and FASTA show close agreement between statistical scores and actual number of errors per query (Fig. 4). The expectation value score gives a good, slightly conservative estimate of the chances of the two sequences being found at random in a given query. Thus, an E-value of 0.01 indicates that roughly one pair of nonhomologs of this similarity should be found in every 100 different queries. Neither raw scores nor percentage identity can be interpreted in this way, and these results validate the suitability of the extreme value distribution for describing the scores from a database search.

The P-values from BLAST also should be directly interpretable but were found to overstate significance by more than two orders of magnitude for 1% EPO for this database. Nonetheless, these results strongly suggest that the analytic theory is fundamentally appropriate. WU-BLAST2 scores were more reliable than those from BLAST, but also exaggerate expected confidence by more than an order of magnitude at 1% EPO.

Overall Detection of Homologs and Comparison of Algorithms. The results in Fig. 5A and Table 1 show that pairwise sequence comparison is capable of identifying only a small fraction of the homologous pairs of sequences in PDB40D-B. Even SSEARCH with E-values, the best protocol tested, could find only 18% of all relationships at a 1% EPO. BLAST, which identifies 15%, was the worst performer, whereas FASTA $k_{\text{up}} = 1$ is nearly as effective as SSEARCH. FASTA $k_{\text{up}} = 2$ and WU-BLAST2 are intermediate in their ability to detect homologs. Comparison of different algorithms indicates that those capable of identifying more homologs are generally slower. SSEARCH is 25 times slower than BLAST and 6.5 times slower than FASTA $k_{\text{up}} = 1$. WU-BLAST2 is slightly faster than FASTA $k_{\text{up}} = 2$, but the latter has more interpretable scores.

In PDB40D-B, where there are many close relationships, the best method can identify only 38% of structurally known homologs (Fig. 5B). The method which finds that many relationships is WU-BLAST2. Consequently, we infer that the differences between FASTA $k_{\text{up}} = 1$, SSEARCH, and WU-BLAST2 programs are unlikely to be significant when compared with variation in database composition and scoring reliability.

Fig. 6 helps to explain why most distant homologs cannot be found by sequence comparison: a great many such relationships have no more sequence identity than would be expected by chance. SSEARCH with E-values can recognize >90% of the homologous pairs with 30–40% identity. In this region, there are 30 pairs of homologous proteins that do not have significant E-values, but 26 of these involve sequences with <50 residues. Of sequences having 25–30% identity, 75% are identified by SSEARCH E-values. However, although the number of homologs grows at lower levels of identity, the detection falls off sharply: only 40% of homologs with 20–25% identity




FIG. 6. Distribution and detection of homologs in PDB40D-B. Bars show the distribution of homologous pairs PDB40D-B according to their identity (using the measure of identity in both). Filled regions indicate the number of these pairs found by the best database searching method (SSEARCH with E-values) at 1% EPO. The PDB40D-B database contains proteins with <40% identity, and as shown on this graph, most structurally identified homologs in the database have diverged extremely far in sequence and have <20% identity. Note that the alignments may be inaccurate, especially at low levels of identity. Filled regions show that SSEARCH can identify most relationships that have 25% or more identity, but its detection wanes sharply below 25%. Consequently, the great sequence divergence of most structurally identified evolutionary relationships effectively defeats the ability of pairwise sequence comparison to detect them.

are detected and only 10% of those with 15–20% can be found. These results show that statistical scores can find related proteins whose identity is remarkably low; however, the power of the method is restricted by the great divergence of many protein sequences.

After completion of this work, a new version of pairwise BLAST was released: BLASTGP (37). It supports gapped alignments, like WU-BLAST2, and dispenses with sum statistics. Our initial tests on BLASTGP using default parameters show that its E-values are reliable and that its overall detection of homologs was substantially better than that of ungapped BLAST, but not quite equal to that of WU-BLAST2.

CONCLUSION

The general consensus amongst experts (see refs. 7, 24, 25, 27 and references therein) suggests that the most effective sequence searches are made by (i) using a large current database in which the protein sequences have been complexity masked and (ii) using statistical scores to interpret the results. Our experiments fully support this view.

Our results also suggest two further points. First, the E-values reported by FASTA and SSEARCH give fairly accurate estimates of the significance of each match, but the P-values provided by BLAST and WU-BLAST2 underestimate the true

Table 1. Summary of sequence comparison methods with PDB40D-B

Method	Relative Time*	1% EPO Cutoff	Coverage at 1% EPO
SSEARCH % identity: within alignment	25.5	>70%	<0.1
SSEARCH % identity: within both	25.5	34%	3.0
SSEARCH % identity: HSSP-scaled	25.5	35% (HSSP = 9.8)	4.0
SSEARCH Smith-Waterman raw scores	25.5	142	10.5
SSEARCH E-values	25.5	0.03	16.4
FASTA $k_{\text{up}} = 1$ E-values	3.9	0.03	17.9
FASTA $k_{\text{up}} = 2$ E-values	1.4	0.03	16.7
WU-BLAST2 P-values	1.1	0.003	17.5
BLAST P-values	1.0	0.00016	14.8

*Times are from large database searches with genome proteins.

extent of errors. Second, SSEARCH, WU-BLAST, and FASTA ktup = 1 perform best, though BLAST and FASTA ktup = 2 detect most of the relationships found by the best procedures and are appropriate for rapid initial searches.

The homologous proteins that are found by sequence comparison can be distinguished with high reliability from the huge number of unrelated pairs. However, even the best database searching procedures tested fail to find the large majority of distant evolutionary relationships at an acceptable error rate. Thus, if the procedures assessed here fail to find a reliable match, it does not imply that the sequence is unique; rather, it indicates that any relatives it might have are distant ones.**

**Additional and updated information about this work, including supplementary figures, may be found at <http://sss.stanford.edu/sss/>.

The authors are grateful to Drs. A. G. Murzin, M. Levitt, S. R. Eddy, and G. Mitchison for valuable discussion. S.E.B. was principally supported by a St. John's College (Cambridge, UK) Benefactors' Scholarship and by the American Friends of Cambridge University. S.E.B. dedicates his contribution to the memory of Rabbi Albert T. and Clara S. Bilgray.

- Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) *J. Mol. Biol.* 215, 403-410.
- Altschul, S. F. & Gish, W. (1996) *Methods Enzymol.* 266, 460-480.
- Pearson, W. R. & Lipman, D. J. (1988) *Proc. Natl. Acad. Sci. USA* 85, 2444-2448.
- Murzin, A. G., Brenner, S. E., Hubbard, T. & Chothia, C. (1995) *J. Mol. Biol.* 247, 536-540.
- Brenner, S. E., Chothia, C., Hubbard, T. J. P. & Murzin, A. G. (1996) *Methods Enzymol.* 266, 635-643.
- Pearson, W. R. (1991) *Genomics* 11, 635-650.
- Pearson, W. R. (1995) *Protein Sci.* 4, 1145-1160.
- Smith, T. F. & Waterman, M. S. (1981) *J. Mol. Biol.* 147, 195-197.
- George, D. G., Hunt, L. T. & Barker, W. C. (1996) *Methods Enzymol.* 266, 41-59.
- Vogt, G., Etzold, T. & Argos, P. (1995) *J. Mol. Biol.* 249, 816-831.
- Henikoff, S. & Henikoff, J. G. (1993) *Proteins* 17, 49-61.
- Bairoch, A. & Apweiler, R. (1996) *Nucleic Acids Res.* 24, 21-25.
- Bairoch, A., Bucher, P. & Hofmann, K. (1996) *Nucleic Acids Res.* 24, 189-196.
- Henikoff, S. & Henikoff, J. G. (1992) *Proc. Natl. Acad. Sci. USA* 89, 10915-10919.
- Dayhoff, M., Schwartz, R. M. & Orcutt, B. C. (1978) in *Atlas of Protein Sequence and Structure*, ed. Dayhoff, M. (National Bio-medical Research Foundation, Silver Spring, MD), Vol. 5, Suppl. 3, pp. 345-352.
- Brenner, S. E. (1996) Ph.D. thesis. (University of Cambridge, UK).
- Sander, C. & Schneider, R. (1991) *Proteins* 9, 56-68.
- Johnson, M. S. & Overington, J. P. (1993) *J. Mol. Biol.* 233, 716-738.
- Barton, G. J. & Sternberg, M. J. E. (1987) *Protein Eng.* 1, 89-94.
- Lesk, A. M., Levitt, M. & Chothia, C. (1986) *Protein Eng.* 1, 77-78.
- Arratia, R., Gordon, L. & M. W. (1986) *Ann. Stat.* 14, 971-993.
- Karlin, S. & Altschul, S. F. (1990) *Proc. Natl. Acad. Sci. USA* 87, 2264-2268.
- Karlin, S. & Altschul, S. F. (1993) *Proc. Natl. Acad. Sci. USA* 90, 5873-5877.
- Altschul, S. F., Boguski, M. S., Gish, W. & Wootton, J. C. (1994) *Nat. Genet.* 6, 119-129.
- Pearson, W. R. (1996) *Methods Enzymol.* 266, 227-258.
- Lipman, D. J., Wilbur, W. J., Smith, T. F. & Waterman, M. S. (1984) *Nucleic Acids Res.* 12, 215-226.
- Wootton, J. C. & Federhen, S. (1996) *Methods Enzymol.* 266, 554-571.
- Waterman, M. S. & Vingron, M. (1994) *Stat. Science* 9, 367-381.
- Perutz, M. F., Kendrew, J. C. & Watson, H. C. (1965) *J. Mol. Biol.* 13, 669-678.
- Abola, E. E., Bernstein, F. C., Bryant, S. H., Koetzle, T. F. & Weng, J. (1987) in *Crystallographic Databases: Information Content, Software Systems, Scientific Applications*, eds. Allen, F. H., Bergerhoff, G. & Sievers, R. (Data Comm. Intl. Union Crystallogr., Cambridge, UK), pp. 107-132.
- Brenner, S. E., Chothia, C. & Hubbard, T. J. P. (1997) *Curr. Opin. Struct. Biol.* 7, 369-376.
- Orengo, C., Michie, A., Jones, S., Jones, D. T., Swindells, M. B. & Thornton, J. (1997) *Structure (London)* 5, 1093-1108.
- Zweig, M. H. & Campbell, G. (1993) *Clin. Chem.* 39, 561-577.
- Gribskov, M. & Robinson, N. L. (1996) *Comput. Chem.* 20, 25-33.
- Fitch, W. M. (1966) *J. Mol. Biol.* 16, 9-16.
- Chung, S. Y. & Subbiah, S. (1996) *Structure (London)* 4, 1123-1127.
- Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W. & Lipman, D. J. (1997) *Nucleic Acids Res.* 25, 3389-3402.
- Girling, R., Schmidt, W., Jr., Houston, T., Amma, E. & Huisman, T. (1979) *J. Mol. Biol.* 131, 417-433.
- Spezio, M., Wilson, D. & Karplus, P. (1993) *Biochemistry* 32, 9906-9916.
- Savle, R. A. & Milner-White, E. J. (1995) *Trends Biochem. Sci.* 20, 374-376.